Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Hemophilia A, congenital


Other Names for this Disease

  • Classic hemophilia
  • Factor 8 deficiency, congenital
  • Factor VIII deficiency, congenital
  • HEM A
  • Hemophilia, classic
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Management Guidelines

  • GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions. Click on the link to view the article on this topic.
  • The National Hemophilia Foundation Web site posts the guidelines for management of pregnancy and delivery of women with bleeding disorders and carriers of hemophilia A and B. Click on the link to view the guidelines.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name antihemophilic factor (recombinant), Fc fusion protein
Trade Name
(Manufacturer Name)
Eloctate
(Biogen Idec Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Generic Name Antihemophilic factor (recombinant)
Trade Name
(Manufacturer Name)
Kogenate FS
(Bayer Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Coagulation Factor VIIa (Recombinant)
Trade Name
(Manufacturer Name)
NovoSeven® RT
(Novo Nordisk, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of bleeding episodes in patients with Factor VII Deficiency. Treatment and peri-operative management of Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.
More Information about this product Drug Information Portal

Generic Name Antihemophilic factor (recombinant)
Trade Name
(Manufacturer Name)
ReFacto®
(Wyeth Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Desmopressin acetate
Trade Name
(Manufacturer Name)
Stimate®
(CSL Behring)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.
More Information about this product Drug Information Portal

Other Names for this Disease
  • Classic hemophilia
  • Factor 8 deficiency, congenital
  • Factor VIII deficiency, congenital
  • HEM A
  • Hemophilia, classic
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.